24-26-GlaxoSmithKline-Intervet India-Advanced Enzyme Technologies
15 June 2010 | News
24
GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline (GSK) Pharmaceutical recorded a total biotech sales revenue of Rs 123.34 crore in the fiscal year ended March 31, 2010. Vaccines has been a key focus area for GSK in the Indian market and it holds 51 percent market share in the Indian vaccine market. Andrew Witty, Global CEO, GSK on his visit to India in in March 2010, said, “India itself is a key priority for GSK itself. This is one of the great emerging economies of the world and will be a great economic story in the next 50 years.” Witty had specifically flown down to Nashik in order to dedicate the new albendazole manufacturing production facility, to the WHO global program to eliminate Lymphatic Filariasis (LF). He has pinned hopes that this would be the starting point and probably in the future he would hope to see more such manufacturing facilities here in India. This new facility, built with an investment of Rs 15 million, will deliver an additional 300 million treatments of albendazole per year. It will double GSK’s annual manufacturing capacity for the LF program.
25
Intervet India
Intervet India’s sales from biotech products stood at Rs 121.66 crore. Intervet India offers a range of products consisting of biologicals, therapeutics, productive hormones to the farming community in the country. Intervet India, is a 100 percent subsidiary of Intervet International with its headquarters at Boxmeer, Netherlands.
Intervet India has a factory producing biologicals, specially FMD vaccine located at Wagholi near Pune. As of the latest news, Intervet has stopped manufacturing poultry vaccines in India and now imports vaccines and markets them in the country. The distribution of Intervet’s products takes place through a network of agents ensuring cold chain maintenance and subsequent distribution through 900 distributors. Intervet India had also entered into a partnership with an NGO, BAIF Development Research Foundation to improve disease management and productivity at rural level, as well as promoting livestock healthcare awareness. The partnership also offers self-employed farmers in remote villages to access to vital veterinary products at a fair price.
26
Advanced Enzyme Technologies
Advanced Enzymes Technologies Limited (AETL) registered a total sales revenue of Rs 121 crore for the fiscal 2009-2010 as against Rs 88.6 crore in 2008-2009. AETL is a research driven company having global leadership in manufacturing enzymes and probiotics. AETL operates in four key verticals: human healthcare, animal healthcare, food processing and industrial processing. For each of these verticals they have created subsidiaries which focus exclusively on delivering solutions to the industries that operate within that vertical. Exports constitutes a major part of the sales for AETL. The US has a major geographical share for AETL’s exports which is around 50-60 percent in totality. The company also spends around 10-12 percent of their total turnover on R&D. Catering to a worldwide market in geographies like Europe, America, China and India, AETL, specializes in providing customized, eco-safe solutions across various industries.
AETL has multi-disciplinary R&D team consisting of microbiologists, biochemists, chemical engineers, food technologists, and biotechnologists with several years of experience with enzyme technology.
GlaxoSmithKline Pharmaceuticals
| CEO | Dr Hasit Joshipura |
 |
| Business | Sales of vaccines | |
| Start-up Year | 2001 | |
| Biotech Revenue | Rs 123.34 crore | |
| Address | Dr Annie Besant Road, Worli, Mumbai-40030 |
|
| Tel | +91-22-24959205 | |
| Fax | +91-22-24914863 | |
| Website | www.gsk-india.com |
GlaxoSmithKline (GSK) Pharmaceutical recorded a total biotech sales revenue of Rs 123.34 crore in the fiscal year ended March 31, 2010. Vaccines has been a key focus area for GSK in the Indian market and it holds 51 percent market share in the Indian vaccine market. Andrew Witty, Global CEO, GSK on his visit to India in in March 2010, said, “India itself is a key priority for GSK itself. This is one of the great emerging economies of the world and will be a great economic story in the next 50 years.” Witty had specifically flown down to Nashik in order to dedicate the new albendazole manufacturing production facility, to the WHO global program to eliminate Lymphatic Filariasis (LF). He has pinned hopes that this would be the starting point and probably in the future he would hope to see more such manufacturing facilities here in India. This new facility, built with an investment of Rs 15 million, will deliver an additional 300 million treatments of albendazole per year. It will double GSK’s annual manufacturing capacity for the LF program.
25
Intervet India
| MD | Dr Lino Componovo |  |
| Business | R&D and manufacturing of veterinary biologicals |
|
| Start-up Year | 1997 | |
| Biotech Revenue | Rs 121.66 crore | |
| Address | Intervet House, 33, Pune-Nagar Road, (Behind
Eden Gardens), Pune - 411 014 |
|
| Tel | +91-20-66050400-01 | |
| Fax | +91-20-66050410 | |
| Website | www.intervet.co.in |
Intervet India’s sales from biotech products stood at Rs 121.66 crore. Intervet India offers a range of products consisting of biologicals, therapeutics, productive hormones to the farming community in the country. Intervet India, is a 100 percent subsidiary of Intervet International with its headquarters at Boxmeer, Netherlands.
Intervet India has a factory producing biologicals, specially FMD vaccine located at Wagholi near Pune. As of the latest news, Intervet has stopped manufacturing poultry vaccines in India and now imports vaccines and markets them in the country. The distribution of Intervet’s products takes place through a network of agents ensuring cold chain maintenance and subsequent distribution through 900 distributors. Intervet India had also entered into a partnership with an NGO, BAIF Development Research Foundation to improve disease management and productivity at rural level, as well as promoting livestock healthcare awareness. The partnership also offers self-employed farmers in remote villages to access to vital veterinary products at a fair price.
26
Advanced Enzyme Technologies
| CEO | Dr CL Rathi |  |
| Business | R&D, manufacturing and marketing of enzymes |
|
| Start-up Year | 1989 | |
| Biotech Revenue | Rs 121 crore | |
| Address | Sun Magnetica, A Wing, 5th floor, LIC Service Rd,
Louiswadi, Thane (W)- 400 604 |
|
| Tel | +91-22-41703200 | |
| Fax | +91-22-25835159 | |
| Website | www.enzyme.com |
Advanced Enzymes Technologies Limited (AETL) registered a total sales revenue of Rs 121 crore for the fiscal 2009-2010 as against Rs 88.6 crore in 2008-2009. AETL is a research driven company having global leadership in manufacturing enzymes and probiotics. AETL operates in four key verticals: human healthcare, animal healthcare, food processing and industrial processing. For each of these verticals they have created subsidiaries which focus exclusively on delivering solutions to the industries that operate within that vertical. Exports constitutes a major part of the sales for AETL. The US has a major geographical share for AETL’s exports which is around 50-60 percent in totality. The company also spends around 10-12 percent of their total turnover on R&D. Catering to a worldwide market in geographies like Europe, America, China and India, AETL, specializes in providing customized, eco-safe solutions across various industries.
AETL has multi-disciplinary R&D team consisting of microbiologists, biochemists, chemical engineers, food technologists, and biotechnologists with several years of experience with enzyme technology.
